News and Events
News
Patient and Healthcare Provider Convenience Focus of Packaging Enhancements
for Humate-P from CSL Behring
November 9, 2009
Read Press Release
National Hemophilia Foundation Applauds First von Willebrand Disease Clinical
Practice Guidelines Issued by NHLBI
May 6, 2008
Read Press Release
Humate-P® Package Notification
Wednesday, July 25, 2007
Read Press Release
Humate-P® Approved to Prevent Excessive Bleeding in VWD Patients
Undergoing Surgery
Monday, April 30, 2007
Read Press Release
Updated Prescribing
Information
CSL Behring Announces Availability of Humate-P®
with Smaller Diluent
February 15, 2006
Read Press Release
Events
To stay informed about the latest news in bleeding disorders, you may be interested
in attending the conferences and meetings listed below.* CSL Behring will be participating
in all of these events, so please stop by our exhibit booth and get information
on Humate-P®, speak with a CSL Behring representative, or obtain brochures.
Hemophilia Federation of America
HFA 2010 Annual Meeting and Educational Symposium
April 22-24, 2010
Westin Crown Center
1 East Pershing Road
Kansas City, MO
www.hemophiliafed.org
World Federation of Hemophilia
July 10-14, 2010
La Rural Convention & Exhibition Centre
Av. Sarmiento 2704
Buenos Aires, Argentina
National Hemophilia Foundation
Annual Meeting
November 11-13, 2010
New Orleans, LA
www.hemophilia.org
*Upcoming conference dates will be posted when they become available.
Most local hemophilia chapters have a Web site, which typically includes a calendar
of events. To find a chapter near you, go to the National Hemophilia Foundation
Web site at: www.hemophilia.org/chapters
Important Safety Information
Humate-P is indicated for treatment and prevention of bleeding in adult patients
with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and
pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous
and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during
and after surgery. This applies to patients with severe VWD, and patients with mild
and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.
Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.
Humate-P is contraindicated in individuals with a history of anaphylactic or severe
systemic response to antihemophilic factor or von Willebrand factor preparations.
Monitor for intravascular hemolysis and decreasing hematocrit values in patients
with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor
VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.
Thromboembolic events have been reported in VWD patients receiving coagulation factor
replacement. Caution should be exercised and antithrombotic measures considered,
particularly in patients with known risk factors for thrombosis.
Humate-P is derived from human plasma. The risk of transmission of infectious agents,
including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent,
cannot be completely eliminated.
In patients receiving Humate-P in clinical studies for treatment of VWD, the most
commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic
reactions, including urticaria (hives), chest tightness, rash, pruritus (itching),
and edema (swelling). For patients undergoing surgery, the most common adverse reactions
are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).
Please see full prescribing
information.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
© CSL Behring 2010. The product information presented on this site is intended for US residents only.